Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen

Noton Dutta, Abdullah Alsultan, Thomas J. Gniadek, Deborah A Belchis, Michael L. Pinn, Khisimuzi E. Mdluli, Eric Nuermberger, Charles A. Peloquin, Petros Karakousis

Research output: Contribution to journalArticle

Abstract

Strategies involving new drug combinations, as well as new uses of existing drugs, are urgently needed to reduce the time required to cure patients with drug-sensitive or multidrug-resistant (MDR) tuberculosis (TB). We compared the sterilizing activity of the standard first-line antitubercular regimen, rifampin-isoniazid-pyrazinamide (RHZ), with that of the novel regimen PA-824-moxifloxacin-pyrazinamide (PaMZ), which is currently being studied in clinical trials (NCT01498419), in the guinea pig model of chronic TB infection, in which animals develop necrotic granulomas histologically resembling their human counterparts. Guinea pigs were aerosol infected with 2 log10 bacilli of wild-type Mycobacterium tuberculosis H37Rv, and antibiotic treatment was initiated 6 weeks after infection. Separate groups of animals received RHZ, PaMZ, or single or two-drug components of the latter regimen administered at human-equivalent doses 5 days/week for a total of 8 weeks. Relapse rates were assessed 3 months after discontinuation of treatment to determine the sterilizing activity of each combination regimen. PaMZ given at human-equivalent doses was safe and well tolerated for the entire treatment period and rendered guinea pig lungs culture negative more rapidly than RHZ did. After 1 month of treatment, 80% and 50% of animals in the RHZ and PaMZ groups, respectively, had lung culture-positive relapse. Both combination regimens prevented microbiological relapse when administered for a total of 2 months. Our data support the use of PaMZ as a novel isoniazid-and rifamycin-sparing regimen suitable for treatment of both drug-sensitive TB and MDR-TB.

Original languageEnglish (US)
Pages (from-to)3910-3916
Number of pages7
JournalAntimicrobial Agents and Chemotherapy
Volume57
Issue number8
DOIs
StatePublished - Aug 2013

Fingerprint

Pyrazinamide
Guinea Pigs
Tuberculosis
Multidrug-Resistant Tuberculosis
Isoniazid
Recurrence
Pharmaceutical Preparations
Therapeutics
Lung
Drug Combinations
Rifampin
Infection
Granuloma
Aerosols
Mycobacterium tuberculosis
Bacillus
rifamycin SV
2-nitro-6-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo(2,1-b)(1,3)oxazine
moxifloxacin
Clinical Trials

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen. / Dutta, Noton; Alsultan, Abdullah; Gniadek, Thomas J.; Belchis, Deborah A; Pinn, Michael L.; Mdluli, Khisimuzi E.; Nuermberger, Eric; Peloquin, Charles A.; Karakousis, Petros.

In: Antimicrobial Agents and Chemotherapy, Vol. 57, No. 8, 08.2013, p. 3910-3916.

Research output: Contribution to journalArticle

Dutta, Noton ; Alsultan, Abdullah ; Gniadek, Thomas J. ; Belchis, Deborah A ; Pinn, Michael L. ; Mdluli, Khisimuzi E. ; Nuermberger, Eric ; Peloquin, Charles A. ; Karakousis, Petros. / Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen. In: Antimicrobial Agents and Chemotherapy. 2013 ; Vol. 57, No. 8. pp. 3910-3916.
@article{eb031cfbff5f47f0847a5ed08eb35513,
title = "Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen",
abstract = "Strategies involving new drug combinations, as well as new uses of existing drugs, are urgently needed to reduce the time required to cure patients with drug-sensitive or multidrug-resistant (MDR) tuberculosis (TB). We compared the sterilizing activity of the standard first-line antitubercular regimen, rifampin-isoniazid-pyrazinamide (RHZ), with that of the novel regimen PA-824-moxifloxacin-pyrazinamide (PaMZ), which is currently being studied in clinical trials (NCT01498419), in the guinea pig model of chronic TB infection, in which animals develop necrotic granulomas histologically resembling their human counterparts. Guinea pigs were aerosol infected with 2 log10 bacilli of wild-type Mycobacterium tuberculosis H37Rv, and antibiotic treatment was initiated 6 weeks after infection. Separate groups of animals received RHZ, PaMZ, or single or two-drug components of the latter regimen administered at human-equivalent doses 5 days/week for a total of 8 weeks. Relapse rates were assessed 3 months after discontinuation of treatment to determine the sterilizing activity of each combination regimen. PaMZ given at human-equivalent doses was safe and well tolerated for the entire treatment period and rendered guinea pig lungs culture negative more rapidly than RHZ did. After 1 month of treatment, 80{\%} and 50{\%} of animals in the RHZ and PaMZ groups, respectively, had lung culture-positive relapse. Both combination regimens prevented microbiological relapse when administered for a total of 2 months. Our data support the use of PaMZ as a novel isoniazid-and rifamycin-sparing regimen suitable for treatment of both drug-sensitive TB and MDR-TB.",
author = "Noton Dutta and Abdullah Alsultan and Gniadek, {Thomas J.} and Belchis, {Deborah A} and Pinn, {Michael L.} and Mdluli, {Khisimuzi E.} and Eric Nuermberger and Peloquin, {Charles A.} and Petros Karakousis",
year = "2013",
month = "8",
doi = "10.1128/AAC.00761-13",
language = "English (US)",
volume = "57",
pages = "3910--3916",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "8",

}

TY - JOUR

T1 - Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen

AU - Dutta, Noton

AU - Alsultan, Abdullah

AU - Gniadek, Thomas J.

AU - Belchis, Deborah A

AU - Pinn, Michael L.

AU - Mdluli, Khisimuzi E.

AU - Nuermberger, Eric

AU - Peloquin, Charles A.

AU - Karakousis, Petros

PY - 2013/8

Y1 - 2013/8

N2 - Strategies involving new drug combinations, as well as new uses of existing drugs, are urgently needed to reduce the time required to cure patients with drug-sensitive or multidrug-resistant (MDR) tuberculosis (TB). We compared the sterilizing activity of the standard first-line antitubercular regimen, rifampin-isoniazid-pyrazinamide (RHZ), with that of the novel regimen PA-824-moxifloxacin-pyrazinamide (PaMZ), which is currently being studied in clinical trials (NCT01498419), in the guinea pig model of chronic TB infection, in which animals develop necrotic granulomas histologically resembling their human counterparts. Guinea pigs were aerosol infected with 2 log10 bacilli of wild-type Mycobacterium tuberculosis H37Rv, and antibiotic treatment was initiated 6 weeks after infection. Separate groups of animals received RHZ, PaMZ, or single or two-drug components of the latter regimen administered at human-equivalent doses 5 days/week for a total of 8 weeks. Relapse rates were assessed 3 months after discontinuation of treatment to determine the sterilizing activity of each combination regimen. PaMZ given at human-equivalent doses was safe and well tolerated for the entire treatment period and rendered guinea pig lungs culture negative more rapidly than RHZ did. After 1 month of treatment, 80% and 50% of animals in the RHZ and PaMZ groups, respectively, had lung culture-positive relapse. Both combination regimens prevented microbiological relapse when administered for a total of 2 months. Our data support the use of PaMZ as a novel isoniazid-and rifamycin-sparing regimen suitable for treatment of both drug-sensitive TB and MDR-TB.

AB - Strategies involving new drug combinations, as well as new uses of existing drugs, are urgently needed to reduce the time required to cure patients with drug-sensitive or multidrug-resistant (MDR) tuberculosis (TB). We compared the sterilizing activity of the standard first-line antitubercular regimen, rifampin-isoniazid-pyrazinamide (RHZ), with that of the novel regimen PA-824-moxifloxacin-pyrazinamide (PaMZ), which is currently being studied in clinical trials (NCT01498419), in the guinea pig model of chronic TB infection, in which animals develop necrotic granulomas histologically resembling their human counterparts. Guinea pigs were aerosol infected with 2 log10 bacilli of wild-type Mycobacterium tuberculosis H37Rv, and antibiotic treatment was initiated 6 weeks after infection. Separate groups of animals received RHZ, PaMZ, or single or two-drug components of the latter regimen administered at human-equivalent doses 5 days/week for a total of 8 weeks. Relapse rates were assessed 3 months after discontinuation of treatment to determine the sterilizing activity of each combination regimen. PaMZ given at human-equivalent doses was safe and well tolerated for the entire treatment period and rendered guinea pig lungs culture negative more rapidly than RHZ did. After 1 month of treatment, 80% and 50% of animals in the RHZ and PaMZ groups, respectively, had lung culture-positive relapse. Both combination regimens prevented microbiological relapse when administered for a total of 2 months. Our data support the use of PaMZ as a novel isoniazid-and rifamycin-sparing regimen suitable for treatment of both drug-sensitive TB and MDR-TB.

UR - http://www.scopus.com/inward/record.url?scp=84880292737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880292737&partnerID=8YFLogxK

U2 - 10.1128/AAC.00761-13

DO - 10.1128/AAC.00761-13

M3 - Article

C2 - 23733473

AN - SCOPUS:84880292737

VL - 57

SP - 3910

EP - 3916

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 8

ER -